BridgeBio Pharma, Inc.
BBIO
Kedudukan dalam Saham
#1648
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Harga Saham
$66.46
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$12.99B
Perubahan (1 hari)
-1.00%
Perubahan (1 tahun)
21.01%
Negara
US
Perdagangan BridgeBio Pharma, Inc. (BBIO)
Kategori
Healthcare
Margin Operasi untuk BridgeBio Pharma, Inc. (BBIO)
Margin Operasi pada October 2026 TTM: -76.22%
Menurut laporan kewangan dan harga saham terkini BridgeBio Pharma, Inc., margin operasi semasa (TTM) ialah -76.22%. Pada akhir 2023, margin operasi syarikat ialah -6,528.75%.
Sejarah Margin Operasi untuk BridgeBio Pharma, Inc. dari 2017 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Ubah |
|---|---|---|
| 2026 (TTM) | -76.22% | -71.48% |
| 2024 | -267.22% | -95.91% |
| 2023 | -6,528.75% | 974.32% |
| 2022 | -607.71% | -26.92% |
| 2021 | -831.58% | -85.54% |
| 2020 | -5,751.99% | 776.28% |
| 2019 | -656.41% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat | Margin Operasi | Perbezaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -100.51% |
US
|
|
| -149.01% | -98.05% |
US
|
|
| 25.57% | -100.34% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.38% |
NL
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.